Form S-1
Expand the disclosure in the first paragraph of this section to disclose that the approval is for specific indications as mentioned in the first risk factor on page 33 and briefly describe the specific indications.
On behalf of Inspire Medical Systems, Inc. (the “Company”), we are providing the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”) with a supplemental submission regarding the proposed disclosure of the Company’s estimated results for the quarter ended March 31, 2018. We have attached as Exhibit A to this letter a draft of the “Prospectus Summary—Preliminary Financial Results for the First Quarter Ended March 31, 2018” section that presents a range of the Company’s estimated revenue, gross margin, operating loss and net loss for the three months ended March 31, 2018, compared to the Company’s revenue, gross margin,One letter for all the questions, without numbered answers. Read the replyRest of the letter
operating loss and net loss for the three months ended March 31, 2017, and the Company’s estimated cash, cash equivalents and short-term investments and principal and interest outstanding under its credit facility as of March 31, 2018. The Company expects to provide this information to potential investors by including it in the preliminary prospectus for the Company’s initial public offering.
Please tell us whether the peer-reviewed articles that you reference are based upon data provided by you or by unrelated third parties. Also, tell us whether there are other peerreviewed articles or other information available about your system, especially those that address any negative findings relating to your system.
See the reply above.
Clearly explain each step you must take to commercialize your technology, including the material hurdles you must overcome at relevant junctures. If such information is appropriate for your prospectus summary, carefully consider the information that is the most significant, and briefly highlight that information in the summary and include more detailed disclosure elsewhere in your prospectus.
See the reply above.
You disclose that four sponsored and more than five independent clinical studies have evaluated more than 750 patients using your treatment. Please clarify how many patients were evaluated in connection with independent studies.
See the reply above.
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
See the reply above.
Tell us whether you commissioned any of the data that you attribute to third parties in your registration statement.
See the reply above.
We note your statement that information in the prospectus is based on industry and general publications and research, surveys and studies conducted by third parties which you have not independently verified. You are responsible for the entire content of the registration statement and should not include language that can be interpreted as a disclaimer of information you have chosen to include. Please revise.
See the reply above.
Disclose the approximate amount of proceeds that you currently intend to use for each purpose mentioned in the second paragraph on page 58. You may reserve the right to change the use of proceeds as described in Instruction7 to Item 504 of Regulation S-K.Rest of the question
If you have no current specific plan for the proceeds, or a significant portion of the proceeds, please say so directly and discuss the principal reasons for this offering.
See the reply above.
Clarify in which jurisdictions you have received the regulatory clearances necessary for your system to be sold.
See the reply above.
Ensure that your disclosure provides the five year background with all information required by Item 401(e) of Regulation S-K. For example, disclose when Mr. McCormick served on the board of directors of Entellus, Nevro and Surmodics.
See the reply above.